Brought to you by 
LeukoSite acquires ProScript for $2.7mm
26 Jul 1999
Executive Summary
LeukoSite (cancer, autoimmune, and inflammatory diseases) will expand its pipeline by acquiring struggling ProScript (small-molecule proteasome inhibitors) for 187,000 shares (priced at $12.29 each when the deal was announced), plus $430,000 in cash.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LeukoSite acquires ProScript for $2.7mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice